/CAMP
CAMP Stock - CAMP4 Therapeutics Corporation
Healthcare|BiotechnologyNASDAQ
$6.38+2.74%
+$0.17 (+2.74%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).69
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+9.7%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CAMP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.32 – $6.44
TARGET (TP)$7.00
STOP LOSS$5.87
RISK/REWARD1:1.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.29
52W High$7.69
52W Low$1.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $652,000 | $350,000 | N/A | $295.84M | $308.59M |
| Gross Profit | $652,000 | $350,000 | N/A | $121.89M | $122.41M |
| Gross Margin | 100.0% | 100.0% | N/A | 41.2% | 39.7% |
| Operating Income | $-53,088,000 | $-51,879,000 | $-45,001,000 | $-15,313,000 | $-3,869,000 |
| Net Income | $-51,791,000 | $-49,291,000 | $-44,192,000 | $-31,148,000 | $-21,157,000 |
| Net Margin | -7943.4% | -14083.1% | N/A | -10.5% | -6.9% |
| EPS | $-2.66 | $-4.07 | $-0.90 | $-0.88 | $-0.62 |
Company Overview
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$13
Average Target
↑ 106.9% Upside
Now
$7
Low
$13
Average
$23
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 2nd 2025 | Cantor Fitzgerald | Initiation | Overweight | $7 |
| September 16th 2025 | JP Morgan | Downgrade | Neutral | - |
| May 27th 2025 | Wedbush | Initiation | Outperform | $8 |
| November 5th 2024 | William Blair | Initiation | Outperform | - |
| November 5th 2024 | Piper Sandler | Initiation | Overweight | $18 |
| November 5th 2024 | JP Morgan | Initiation | Overweight | $23 |
| August 16th 2022 | Craig Hallum | Upgrade | Buy | $10← $8 |
Earnings History & Surprises
CAMPBeat Rate
53%
Last 19 quarters
Avg Surprise
-60.3%
EPS vs Estimate
Beats / Misses
10/9
Last 12 quarters
Latest EPS
$-0.55
Q4 2025
EPS Surprise History
Q1 24
-70.0%
$-3.91vs$-2.30
Q2 24
+49.7%
$-1.03vs$-2.04
Q3 24
-75.0%
$-1.61vs$-0.92
Q4 24
+35.6%
$-0.69vs$-1.07
Q1 25
-211.0%
$-2.83vs$-0.91
Q2 25
+11.4%
$-0.62vs$-0.70
Q3 25
+7.5%
$-0.62vs$-0.67
Q4 25
-17.0%
$-0.55vs$-0.47
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.35 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.47 | $-0.55 | -17.0% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.67 | $-0.62 | +7.5% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.70 | $-0.62 | +11.4% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.91 | $-2.83 | -211.0% | ✗ MISS |
Q4 2024 | Oct 11, 2024 | $-1.07 | $-0.69 | +35.6% | ✓ BEAT |
Q3 2024 | Jul 8, 2024 | $-0.92 | $-1.61 | -75.0% | ✗ MISS |
Q2 2024 | Jun 6, 2024 | $-2.04 | $-1.03 | +49.7% | ✓ BEAT |
Q1 2024 | Jan 9, 2024 | $-2.30 | $-3.91 | -70.0% | ✗ MISS |
Q4 2023 | Oct 5, 2023 | $-0.00 | $-0.01 | -133.1% | ✗ MISS |
Q3 2023 | Jul 10, 2023 | $0.92 | $-0.23 | -125.0% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $0.23 | $1.38 | +500.0% | ✓ BEAT |
Q2 2023 | Apr 19, 2023 | $0.03 | $-0.13 | -533.9% | ✗ MISS |
Q4 2022 | Dec 20, 2022 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q3 2022 | Sep 22, 2022 | $-0.92 | $-0.46 | +50.0% | ✓ BEAT |
Q2 2022 | Jun 23, 2022 | $-1.15 | $-2.30 | -100.0% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $-1.38 | $-0.23 | +83.3% | ✓ BEAT |
Q4 2021 | Dec 21, 2021 | $-0.23 | $-1.84 | -700.0% | ✗ MISS |
Q3 2021 | Sep 23, 2021 | $1.38 | $1.84 | +33.3% | ✓ BEAT |
Q2 2021 | Jun 24, 2021 | $1.61 | $1.84 | +14.3% | ✓ BEAT |
Latest News
UPDATE: CAMP4 Therapeutics Partners With GSK To Develop ASO Therapies For Neurodegenerative And Renal Diseases; Secures $17.5M Upfront
📈 PositiveBenzinga•Dec 18, 2025, 01:32 PM•Also:
CAMP4 Therapeutics Prices $30M Underwritten Offering Of 5M Shares At $6.00 Each
➖ NeutralBenzinga•Dec 18, 2025, 12:11 PM
CAMP4 Therapeutics Enters Into Strategic Research, Collaboration And License Agreement With GSK To Identify, Develop ASO Drug Candidates For Multiple Gene Targets Relevant To Neurodegenerative And Kidney Disease Indications
📈 PositiveBenzinga•Dec 18, 2025, 12:03 PM•Also:
CAMP4 Therapeutics Corp To Offer Up To $300M In Securities
📈 PositiveBenzinga•Nov 10, 2025, 10:20 PM
CAMP stock has given up its prior loss. CAMP4 Therapeutics shares were trading lower.
➖ NeutralBenzinga•Nov 7, 2025, 08:12 PM
CAMP4 Therapeutics shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 7, 2025, 04:20 PM
Camp4 Therapeutics Q3 EPS $(0.55) Beats $(0.68) Estimate, Sales $795.000K Beat $480.000K Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:35 PM
Cantor Fitzgerald Initiates Coverage On Camp4 Therapeutics with Overweight Rating, Announces Price Target of $7
📈 PositiveBenzinga•Oct 2, 2025, 12:38 PM
CAMP4 Therapeutics Initiates Toxicology Studies For CMP-SYNGAP-01
➖ NeutralBenzinga•Oct 1, 2025, 12:09 PM
JP Morgan Downgrades Camp4 Therapeutics to Neutral
📉 NegativeBenzinga•Sep 16, 2025, 10:41 AM•Also:
Piper Sandler Maintains Overweight on Camp4 Therapeutics, Lowers Price Target to $12
➖ NeutralBenzinga•Sep 15, 2025, 12:48 PM
CAMP4 Therapeutics shares are trading higher after the company announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors for up to $100 million in gross proceeds through a private placement.
📈 PositiveBenzinga•Sep 10, 2025, 01:09 PM
CAMP4 Therapeutics Secures $50M Initial Financing With Potential For Additional $50M To Fund SYNGAP1 Phase 1/2 Clinical Trial
📈 PositiveBenzinga•Sep 10, 2025, 11:11 AM
Camp4 Reports Q2 Revenue Beats Estimates
📈 PositiveThe Motley Fool•Aug 14, 2025, 08:39 PM
Frequently Asked Questions about CAMP
What is CAMP's current stock price?
CAMP4 Therapeutics Corporation (CAMP) is currently trading at $6.38 per share. The stock has moved +2.74% today.
What is the analyst price target for CAMP?
The average analyst price target for CAMP is $7.00, based on 1 analyst.
What sector is CAMP4 Therapeutics Corporation in?
CAMP4 Therapeutics Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CAMP's market cap?
CAMP4 Therapeutics Corporation has a market capitalization of $0.14 billion, making it a small-cap company.
Does CAMP pay dividends?
No, CAMP4 Therapeutics Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
ATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
HYFT
MindWalk Holdings Corp.
$1.67
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
UNCY
Unicycive Therapeutics, Inc.
$5.56
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
Explore stocks similar to CAMP for comparison